Initiating Azathioprine for Crohn's Disease

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 5, 2012, Pages 460-465

  Levesque, Barrett G ^a   Loftus, Edward V ^b  

^a SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

6 Mercaptopurine; 6 Methylmercaptopurine; 6 Thioguanine; Azathioprine; Crohn's Disease; Thiopurine Methyltransferase

Indexed keywords

6 THIOGUANINE NUCLEOTIDE; ADALIMUMAB; ALLOPURINOL; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; INFLUENZA VACCINE; MERCAPTOPURINE; METHOTREXATE; METHYLMERCAPTOPURINE; NATALIZUMAB; PLACEBO; PURINE DERIVATIVE; THIOPURINE METHYLTRANSFERASE; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE;

ARTHRALGIA; ARTICLE; BIOLOGICAL THERAPY; BONE MARROW TOXICITY; CHICKENPOX; CROHN DISEASE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG WITHDRAWAL; ENZYME ASSAY; GASTROINTESTINAL SURGERY; HUMAN; INFLUENZA; LEUKOPENIA; LIVER TOXICITY; LYMPHOMA; NAUSEA; NEUTROPENIA; PANCREATITIS; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; REMISSION; RISK ASSESSMENT; T CELL LYMPHOMA; THROMBOCYTOPENIA; VERRUCA VULGARIS;

EID: 84859870647     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.01.018     Document Type: Article

References (45)

1. J. Cosnes S. Cattan A. Blain Long-term evolution of disease behavior of Crohn's disease Inflamm Bowel Dis 8 2002 244 250
2. K.T. Thia W.J. Sandborn W.S. Harmsen Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort Gastroenterology 139 2010 1147 1155
3. C. Sies C. Florkowski P. George Measurement of thiopurine methyl transferase activity guides dose-initiation and prevents toxicity from azathioprine N Z Med J 118 2005 U1324
4. W.J. Sandborn A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate Am J Gastroenterol 91 1996 423 433
5. R.K. Weersma F.T. Peters L.E. Oostenbrug Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases Aliment Pharmacol Ther 20 2004 843 850
6. F. Bermejo A. Lopez-Sanroman C. Taxonera Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis Aliment Pharmacol Ther 28 2008 623 628
7. U. Hindorf M. Johansson A. Eriksson Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease Aliment Pharmacol Ther 29 2009 654 661
8. J.D. Lewis O. Abramson M. Pascua Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations Clin Gastroenterol Hepatol 7 2009 1195 1201 quiz, 1141–1142
9. L. Beaugerie N. Brousse A.M. Bouvier Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study Lancet 374 2009 1617 1625
10. A.C. Mackey L. Green L.C. Liang Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease J Pediatr Gastroenterol Nutr 44 2007 265 267
11. M.D. Long H.H. Herfarth C.A. Pipkin Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease Clin Gastroenterol Hepatol 8 2010 268 274
12. M.D. Long M.D. Kappelman C.A. Pipkin Nonmelanoma skin cancer in inflammatory bowel disease: a review Inflamm Bowel Dis 17 2011 1423 1427
13. J. Bhatia J. Bratcher B. Korelitz Abnormalities of uterine cervix in women with inflammatory bowel disease World J Gastroenterol 12 2006 6167 6171
14. S. Kane B. Khatibi D. Reddy Higher incidence of abnormal pap smears in women with inflammatory bowel disease Am J Gastroenterol 103 2008 631 636
15. C.W. Lees J. Critchley N. Chee Lack of association between cervical dysplasia and IBD: a large case-control study Inflamm Bowel Dis 15 2009 1621 1629
16. P.J. Baiocco B.I. Korelitz The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome J Clin Gastroenterol 6 1984 211 216
17. M.C. Bush S. Patel R.H. Lapinski Perinatal outcomes in inflammatory bowel disease J Matern Fetal Neonatal Med 15 2004 237 241
18. J. Coelho L. Beaugerie J.F. Colombel Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME study Gut 60 2011 198 203
19. G.Y. Melmed A.F. Ippoliti K.A. Papadakis Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses Am J Gastroenterol 101 2006 1834 1840
20. S.K. Wasan S.E. Baker P.R. Skolnik A practical guide to vaccinating the inflammatory bowel disease patient Am J Gastroenterol 105 2010 1231 1238
21. L. Lennard The clinical pharmacology of 6-mercaptopurine Eur J Clin Pharmacol 43 1992 329 339
22. R.M. Weinshilboum S.L. Sladek Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity Am J Hum Genet 32 1980 651 662
23. R.A. Booth M.T. Ansari E. Loit Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review Ann Intern Med 154 2011 814 823 W-295–8
24. W.J. Sandborn O.E. Van B.J. Zins An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease Gastroenterology 109 1995 1808 1817
25. C.W. Lees A.K. Maan B. Hansoti Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease Aliment Pharmacol Ther 27 2008 220 227
26. W.J. Sandborn W.J. Tremaine D.C. Wolf Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease North American Azathioprine Study Group Gastroenterology 117 1999 527 535
27. D.C. Pearson G.R. May G.H. Fick Azathioprine and 6-mercaptopurine in Crohn disease A meta-analysis Ann Intern Med 123 1995 132 142
28. R.W. Summers D.M. Switz J.T. Sessions Jr National cooperative Crohn's disease study: results of drug treatment Gastroenterology 77 1979 847 869
29. K.J. Khan M.C. Dubinsky A.C. Ford Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis Am J Gastroenterol 106 2011 630 642
30. E. Prefontaine J.K. Macdonald L.R. Sutherland Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease Cochrane Database Syst Rev 6 2010 CD000545
31. J.F. Colombel W.J. Sandborn W. Reinisch Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 2010 1383 1395
32. M. Lémann J.Y. Mary B. Duclos Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial Gastroenterology 130 2006 1054 1061
33. W.R. Connell M.A. Kamm J.K. Ritchie Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience Gut 34 1993 1081 1085
34. J.F. Colombel N. Ferrari H. Debuysere Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy Gastroenterology 118 2000 1025 1030
35. M.C. Dubinsky S. Lamothe H.Y. Yang Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease Gastroenterology 118 2000 705 713
36. C. Cuffari S. Hunt T. Bayless Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease Gut 48 2001 642 646
37. M.T. Osterman R. Kundu G.R. Lichtenstein Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis Gastroenterology 130 2006 1047 1053
38. S.J. Gardiner R.B. Gearry M.J. Burt Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio J Gastroenterol Hepatol 26 2011 49 54
39. M.P. Sparrow S.A. Hande S. Friedman Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine Clin Gastroenterol Hepatol 5 2007 209 214
40. A. Ansari T. Elliott B. Baburajan Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease Aliment Pharmacol Ther 28 2008 734 741
41. A. Ansari N. Patel J. Sanderson Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease Aliment Pharmacol Ther 31 2010 640 647
42. S.M. Govani P.D. Higgins Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD J Crohns Colitis 4 2010 444 449
43. Y. Leung M.P. Sparrow M. Schwartz Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease J Crohns Colitis 3 2009 162 167
44. S.A. Geller M.C. Dubinsky F.F. Poordad Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease Am J Surg Pathol 28 2004 1204 1211
45. G.R. Lichtenstein M.T. Abreu R. Cohen American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease Gastroenterology 130 2006 935 939